Lung cancer ranks first in the incidence and mortality of cancer in the world, of which more
than 80% are non-small cell lung cancer (NSCLC). The majority of NSCLC patients are in …

Despite recent advances in the treatment of non-small cell lung cancer (NSCLC), less than
10% of patients survive the first five years when the disease has already spread at primary …

Simple Summary Eribulin mesylate, an anti-mitotic drug used for the treatment of metastatic
breast cancer (BC), exhibits significant effects on cancer cell migration, invasion, and …

Objective. To explore the application value of circulating tumor cells (CTCs) and circulating
free DNA (cfDNA) from peripheral blood in the prognosis of advanced gastric cancer (AGC) …

Background Visceral pleural invasion (VPI) is a clinical manifestation associated with a poor
prognosis, and diagnosing it preoperatively is highly imperative for successful sublobar …

Simple Summary Osimertinib has become the standard of care for the first-line treatment of
EGFR-mutant NSCLC patients. The aim of this current translational research study was to …

Lung cancer is one of the most lethal malignancies, with non-small cell lung cancer
(NSCLC) being the most common histologic subtype. Metastasis leads to poor prognosis for …

Purpose: Tusamitamab ravtansine is an antibody–drug conjugate that targets
carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) and delivers a …

In lung cancer diagnosis, folate receptor (FR)–based circulating tumor cell (CTC) has shown
its ability to distinguish malignancy from benign disease to some extent. However, there are …

This paper is the exploration and analysis of the diagnostic value of circulating tumor cells
(CTC) and circulating tumor deoxyribonucleic acid (ctDNA) in early non-small cell lung …